PMID- 35526704 OWN - NLM STAT- MEDLINE DCOM- 20220602 LR - 20220623 IS - 1873-6815 (Electronic) IS - 0531-5565 (Linking) VI - 164 DP - 2022 Jul TI - DPP4 inhibitors as a potential therapeutic option for sarcopenia: A 6-month follow-up study in diabetic older patients. PG - 111832 LID - S0531-5565(22)00140-1 [pii] LID - 10.1016/j.exger.2022.111832 [doi] AB - OBJECTIVES: Sarcopenia is associated with increased morbidity and mortality in older adults with type 2 diabetes mellitus (T2DM). This study investigates the effects of dipeptidyl peptidase-4 inhibitors (DPP4i) as an add-on therapy for sarcopenia in older adults with T2DM over a six-month follow-up period. METHODS: This is a retrospective and six-month follow-up study. The study was performed on 90 participants who are followed in a geriatric clinic hospital. Sarcopenia was diagnosed as per the EGWSOP-2 criteria. The patients were divided into two groups regarding DPP4i use. Each patient was evaluated for sarcopenia and sarcopenia-related parameters at baseline and at the end of 6 months. RESULTS: The mean age of the patients was 72.57 +/- 7.089, and 60% of them were female. DPP4i users had worse glycemic control and decreased rate of low muscle strength at the end of 6 months (39.6% vs. 25.0%, P = .039). Forty-two patients without DPP4i therapy had reduced muscle strength (22.71 +/- 6.95 kg vs. 20.88 +/- 6.32 kg, P = .046) and stable Hba1c levels (6.45 +/- 0.56% vs. 6.40 +/- 0.52, P = .380) at their six-month follow-up control. CONCLUSIONS: Adding DPP4i to treatment for T2DM yields a positive effect on muscle strength and glycemic control. These agents may offer higher prospects in managing T2DM while counteracting sarcopenia. BRIEF SUMMARY: T2DM and Sarcopenia are common in older adults. Considering the increased prevalence of T2DM and the risk of coexistent sarcopenia in older adults, the additional positive effects of DPP4i may be crucial in the choice of treatment for these patients. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Sencan, Canberk AU - Sencan C AD - Department of Internal Medicine, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey. FAU - Dost, Fatma Sena AU - Dost FS AD - Department of Geriatric Medicine, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey; Geriatric Sciences Association, Izmir, Turkey. FAU - Ates Bulut, Esra AU - Ates Bulut E AD - Geriatric Sciences Association, Izmir, Turkey; Department of Geriatric Medicine, Adana State Hospital, Adana, Turkey. FAU - Isik, Ahmet Turan AU - Isik AT AD - Department of Geriatric Medicine, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey; Geriatric Sciences Association, Izmir, Turkey; Alzheimer Foundation, Turkey; Department of Neuroscience, Institute of Health Science, Dokuz Eylul University, Izmir, Turkey. Electronic address: atisik@yahoo.com. LA - eng PT - Journal Article DEP - 20220506 PL - England TA - Exp Gerontol JT - Experimental gerontology JID - 0047061 RN - 0 (Dipeptidyl-Peptidase IV Inhibitors) RN - EC 3.4.14.5 (DPP4 protein, human) RN - EC 3.4.14.5 (Dipeptidyl Peptidase 4) SB - IM MH - Aged MH - *Diabetes Mellitus, Type 2/drug therapy/enzymology MH - *Dipeptidyl Peptidase 4/metabolism MH - *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Retrospective Studies MH - *Sarcopenia/drug therapy/enzymology OTO - NOTNLM OT - DPP4 inhibitors OT - Diabetes mellitus OT - Muscle mass OT - Muscle strength OT - Older adults OT - Sarcopenia EDAT- 2022/05/09 06:00 MHDA- 2022/06/03 06:00 CRDT- 2022/05/08 19:25 PHST- 2022/01/23 00:00 [received] PHST- 2022/04/26 00:00 [revised] PHST- 2022/05/02 00:00 [accepted] PHST- 2022/05/09 06:00 [pubmed] PHST- 2022/06/03 06:00 [medline] PHST- 2022/05/08 19:25 [entrez] AID - S0531-5565(22)00140-1 [pii] AID - 10.1016/j.exger.2022.111832 [doi] PST - ppublish SO - Exp Gerontol. 2022 Jul;164:111832. doi: 10.1016/j.exger.2022.111832. Epub 2022 May 6.